drugset / Trial / NCT01608009
[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess \[18F\] -fluciclatide as a biomarker of response to pazopanib and to evaluate the efficacy and safety of the combination of pazopanib and paclitaxel in platinum-resistant ovarian cancer patients.
Timeline
- Start
- 2012-07
- Primary completion
- 2015-05
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Pazopanib | Small molecule | 800 mg | — |